Clinical trial

Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease

NCT00082602

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-05-01

PhasePHASE3

Study timeline

Study start (unknown)2004-05-01Date precision: month

Registry last updated2011-05-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Alzheimer's Diseaseunresolved

Interventions

galantamine ERDRUG

Sponsors & collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.lead sponsor

Ortho-McNeil Neurologics, Inc.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00082602 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.